Paper37993201
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
Butler J and 23 others. J Am Coll Cardiol, 2023. Cited by 68 papers, by iCite.
Cite this record
ConductScience Library. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. Papers, record 37993201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37993201
- Disease
- obesity disorder354 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Heart Failure | Major topic |
| Humans | |
| Stroke Volume | |
| Ventricular Function, Left | |
| Obesity | |
| Semaglutide |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AG078153 | NIA NIH HHS | United States | R01AG078153 | PubMed and NIH | NIH RePORTER |
| R01 AG018915 | NIA NIH HHS | United States | R01AG018915 | PubMed and NIH | NIH RePORTER |
| R01 AG045551 | NIA NIH HHS | United States | R01AG045551 | PubMed and NIH | NIH RePORTER |
| U01 AG076928 | NIA NIH HHS | United States | U01AG076928 | PubMed and NIH | NIH RePORTER |
| U01 HL160272 | NHLBI NIH HHS | United States | U01HL160272 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04788511 | Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 37993202 | Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide. | https://conductscience.org/library/papers/37993202 |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37203441 | Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. | Circ Heart Fail | 2023 | https://conductscience.org/library/papers/37203441 | PubMed |
| 2 | 24716680 | Spironolactone for heart failure with preserved ejection fraction. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24716680 | PubMed |
| 3 | 37211977 | Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. | Eur J Heart Fail | 2023 | https://conductscience.org/library/papers/37211977 | PubMed |
| 4 | 29431256 | Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. | Eur J Heart Fail | 2018 | https://conductscience.org/library/papers/29431256 | PubMed |
| 5 | 31272568 | Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. | Mayo Clin Proc | 2019 | https://conductscience.org/library/papers/31272568 | PubMed |
| 6 | 28381470 | Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. | Circulation | 2017 | https://conductscience.org/library/papers/28381470 | PubMed |
| 7 | 35500050 | Border Disputes Between Heart Failure Phenotypes. | Circulation | 2022 | https://conductscience.org/library/papers/35500050 | PubMed |
| 8 | 34447992 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. | Eur Heart J | 2021 | https://conductscience.org/library/papers/34447992 | PubMed |
| 9 | 36041474 | SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. | Lancet | 2022 | https://conductscience.org/library/papers/36041474 | PubMed |
| 10 | 13678871 | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. | Lancet | 2003 | https://conductscience.org/library/papers/13678871 | PubMed |
| 11 | 35379504 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | J Am Coll Cardiol | 2022 | https://conductscience.org/library/papers/35379504 | PubMed |
| 12 | 36994635 | Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction. | Eur J Heart Fail | 2023 | https://conductscience.org/library/papers/36994635 | PubMed |
| 13 | 37622681 | Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37622681 | PubMed |
| 14 | 26374849 | Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. | Eur Heart J | 2016 | https://conductscience.org/library/papers/26374849 | PubMed |
| 15 | 37013269 | A reclassification of heart failure based on recognition of heart failure with normal to supernormal ejection fraction, a clinically common form of cardiac contracture, with distinctive pathophysiological and therapeutic features. | Eur J Heart Fail | 2023 | https://conductscience.org/library/papers/37013269 | PubMed |
| 16 | 31736342 | Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. | Circulation | 2020 | https://conductscience.org/library/papers/31736342 | PubMed |
| 17 | 27790809 | Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. | Eur J Heart Fail | 2017 | https://conductscience.org/library/papers/27790809 | PubMed |
| 18 | 31475794 | Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31475794 | PubMed |
| 19 | 37643614 | A big STEP for treatment of heart failure with preserved ejection fraction. | Cell Metab | 2023 | https://conductscience.org/library/papers/37643614 | PubMed |
| 20 | 34878502 | Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. | Eur Heart J | 2022 | https://conductscience.org/library/papers/34878502 | PubMed |
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985589 | Exploration of the Pathogenesis and Treatment of Heart Failure. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42985589 | PubMed |
| 42910211 | Cross-cutting circuits in heart failure with preserved ejection fraction: Integrating adipokine biology, mechanotransduction, and precision targeting. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42910211 | PubMed |
| 42866227 | Bidirectional metabolic-vascular feedback loops in heart failure: From myocardial energetics to multisystem cardiometabolic crosstalk. | iScience | 2026 | https://conductscience.org/library/papers/42866227 | PubMed |
| 42737629 | Mitochondrial Distress Signals at the Heart-Liver Interface: Molecular Links Between MASLD and Heart Failure. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737629 | PubMed |
| 42533336 | Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework. | Cardiovasc Diabetol Endocrinol Rep | 2026 | https://conductscience.org/library/papers/42533336 | PubMed |
| 42292836 | Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42292836 | PubMed |
| 42280332 | GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives. | Nutrients | 2026 | https://conductscience.org/library/papers/42280332 | PubMed |
| 42213282 | Metabolic inflexibility across heart failure phenotypes: mechanisms and type-specific therapeutic implications. | Apoptosis | 2026 | https://conductscience.org/library/papers/42213282 | PubMed |
| 42210124 | Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study. | BMC Cardiovasc Disord | 2026 | https://conductscience.org/library/papers/42210124 | PubMed |
| 42194729 | Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications. | J Clin Med | 2026 | https://conductscience.org/library/papers/42194729 | PubMed |
| 42025516 | Heart Failure With Mildly Reduced Ejection Fraction: A Heart Failure Society of America Scientific Statement. | J Card Fail | 2026 | https://conductscience.org/library/papers/42025516 | PubMed |
| 41939833 | Alpha-7 nicotinic acetylcholine receptor: targeting the interplay between inflammation, renin-angiotensin aldosterone system, and nervous system for the novel treatment of heart failure. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41939833 | PubMed |
| 41733759 | Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management. | Curr Obes Rep | 2026 | https://conductscience.org/library/papers/41733759 | PubMed |
| 41653275 | GLP-1 Mitigated Inflammation and Oxidative Stress in Oral Lichen Planus Via JAK-STAT3 Pathway. | Biochem Genet | 2026 | https://conductscience.org/library/papers/41653275 | PubMed |
| 41566974 | Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management. | Endocrinol Diabetes Metab | 2026 | https://conductscience.org/library/papers/41566974 | PubMed |
| 41501059 | Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. | Nat Commun | 2026 | https://conductscience.org/library/papers/41501059 | PubMed |
| 41379177 | 2025 Brazilian Evidence-based Guideline on the Management of Obesity and Prevention of Cardiovascular Disease and Obesity-Associated Complications: A Position Statement by Five Medical Societies. | Arq Bras Cardiol | 2025 | https://conductscience.org/library/papers/41379177 | PubMed |
| 41304969 | Potential Implications of Body Mass Composition Changes in Heart Failure Patients in the Era of SGLT2i, GLP-1 RA, and GIP/GLP-1 RA. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304969 | PubMed |
| 41254791 | 2025 Brazilian evidence-based guideline on the management of obesity and prevention of cardiovascular disease and obesity-associated complications: a position statement by five medical societies. | Diabetol Metab Syndr | 2025 | https://conductscience.org/library/papers/41254791 | PubMed |
| 41195790 | Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/41195790 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| SEMAGLUTIDE | CHEMBL2108724 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108724 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37993201
GET https://conductscience.org/api/papers/v1/37993201/authors?page=2